Literature DB >> 5443728

Vinblastine in the management of testicular cancer.

M L Samuels, C D Howe.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5443728     DOI: 10.1002/1097-0142(197005)25:5<1009::aid-cncr2820250504>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  8 in total

Review 1.  [Germ cell tumors].

Authors:  Nuria Pardo García; Arturo Muñoz Villa; Maria Soledad Maldonado Regalado
Journal:  Clin Transl Oncol       Date:  2005-09       Impact factor: 3.405

2.  Chemotherapy for non-seminomatous germ-cell tumours.

Authors:  P M Wilkinson
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

3.  Modelling population-based cancer survival trends using join point models for grouped survival data.

Authors:  Binbing Yu; Lan Huang; Ram C Tiwari; Eric J Feuer; Karen A Johnson
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2009-04       Impact factor: 2.483

4.  Combination chemotherapy for testicular tumours.

Authors:  T J McElwain; M J Peckham
Journal:  Proc R Soc Med       Date:  1974-04

Review 5.  Update in cancer chemotherapy: genitourinary tract cancer, Part 4: Testicular cancer.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1988-04       Impact factor: 1.798

6.  Germ cell tumors of the testes.

Authors:  G D Braunstein
Journal:  West J Med       Date:  1977-05

7.  Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.

Authors:  Y Nieto; S-M Tu; R Bassett; R B Jones; A M Gulbis; N Tannir; A Kingham; C Ledesma; K Margolin; L Holmberg; R Champlin; L Pagliaro
Journal:  Ann Oncol       Date:  2015-07-21       Impact factor: 32.976

8.  Treatment of metastatic testicular tumours with bleomycin, etoposide, cisplatin and vincristine (BEPV).

Authors:  B A Price; N H Peters
Journal:  J R Soc Med       Date:  1992-11       Impact factor: 18.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.